Overview

A Phase I Dose-escalation Study of a Single Administration of Extended-Release Injectable Suspension (ND-340)

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study focused on ND-340 extended release injection suspension for patients undergoing total knee arthroplasty with a one-time nerve blockade to assess drug side effects, pharmacokinetics and the effect of pain relief after surgery.
Phase:
Phase 1
Details
Lead Sponsor:
Nang Kuang Pharmaceutical Co., Ltd.